Mandate

Vinge has represented Eleda in connection with the acquisitions of Marbit Aktiebolag, FlexiRail AB, and Hanell Entreprenad i Gävle AB

Vinge has represented the leading infrastructure group Eleda in connection with the acquisitions of Marbit Aktiebolag, FlexiRail AB, and Hanell Entreprenad i Gävle AB from Vestum. These companies are engaged in contracting activities within the construction sector. The total purchase price for the shares amounts to 747 MSEK. All key executives in the companies will become shareholders in Eleda.

Hanell Entreprenad i Gävle AB and FlexiRail AB both have extensive experience in railway maintenance, and Eleda also strengthens its leading position in ground construction in Stockholm through the acquisition of Marbit Aktiebolag.

The transaction is subject to regulatory approvals, and the closing is expected to occur in the first quarter of 2025.

Vinge's team primarily consisted of Christina Kokko, Johanna Wiberg, Eléonore Friberg, Madelene Andersson, and Chris Bastholm (M&A), Niclas Lindblom (Construction), Sara Franson (Real Estate), Hanna Kövamees (Commercial Agreements), Siri Bromberg (GDPR), Calle Tengwall Pagels and William Carlberg Johansson (Banking and Finance), Simon Söderholm and Jessica Jacob (Employment Law), Hayaat Ibrahim and Gulestan Ali (Compliance), Marcus Glader, Daniel Wendelsson, Dagne Sabockis, Lovisa Lewin, and Lovisa Arpi (Competition Law and FDI), and Jasmina Skandrani (Project Assistant).

Read the client's press release here.

Related

Vinge advised Precise Biometrics

Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026